预约演示
更新于：2024-12-12
Pimecrolimus
吡美莫司
更新于：2024-12-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2001-12-13), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C43H68ClNO11 |
InChIKeyKASDHRXLYQOAKZ-XDSKOBMDSA-N |
CAS号137071-32-0 |
关联
79
项与 吡美莫司 相关的临床试验NCT06400511
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis
CTRI/2024/03/063709
A Randomized, Double Blind, Placebo Controlled, Three arm, Parallel, Multicentre, Study to Evaluate the Bioequivalence using Clinical Endpoint of Pimecrolimus Cream, 1% of Encube Ethicals Private Limited, India to Pimecrolimus Cream, 1% of Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA in Treatment of Mild to Moderate Atopic Dermatitis. - Nil
NCT06241118
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
100 项与 吡美莫司 相关的临床结果
登录后查看更多信息
100 项与 吡美莫司 相关的转化医学
登录后查看更多信息
100 项与 吡美莫司 相关的专利（医药）
登录后查看更多信息
878
项与 吡美莫司 相关的文献（医药）2024-06-28Cureus Journal of Medical Science
Resolution of Discoid Lupus Alopecia With Systemic Hydroxychloroquine and Topical Pimecrolimus Combination Therapy
Article
作者: Hilts, Alexis ; Lee, Cynthia ; Greenberg, H L ; Liang, Kristine R
Discoid lupus erythematosus (DLE) is an autoimmune skin condition that is typically part of the cutaneous manifestation of systemic lupus erythematosus (SLE). DLE is characterized by erythematous patches that can progress to depigmentation and alopecia, leading to scarring and permanent hair loss if left untreated. Herein, we present a unique case of localized DLE on the scalp in a 46-year-old female with no prior history of autoimmune disorders. The patient underwent several medication trials, including intralesional corticosteroids, topical calcineurin inhibitors, topical corticosteroids, and systemic hydroxychloroquine, with limited success in treating her discoid alopecia. Subsequently, a combination therapy of oral hydroxychloroquine and topical pimecrolimus significantly improved her scalp lesion. This case highlights the efficacy of combination therapy in managing localized DLE, providing valuable insights for future research focused on DLE alopecia management and optimizing treatment strategies for similar cases.
2024-05-06Journal of burn care & research : official publication of the American Burn Association
Nonsurgical Treatment of Postburn Hypopigmentation: A Literature Review
Review
作者: Cetrulo, Curtis L ; Camuzard, Olivier ; Lellouch, Alexandre G ; Berkane, Yanis ; Vaillant, Camille ; Lupon, Elise ; Chaput, Benoît ; Bertheuil, Nicolas
Abstract:
The treatment of postburn hypopigmentation was primarily surgical before the advent of new technologies. Medical devices and therapies are emerging to manage scar sequelae that can be disfiguring and associated with severe psychosocial impact. These innovations have been poorly investigated for hypopigmentation, but they represent a real hope. We reviewed all articles published on Pubmed up to June 2022. Included studies had to specifically focus on treating postburn hypopigmented scars. All articles evaluating transient solutions such as make-up, and articles describing inflammation-linked hypopigmentation with no etiological details or no burn injury history were excluded. Through this review, we have highlighted 6 different types of nonsurgical treatments reported in postburn leukoderma potentially allowing definitive results. Electrophoto-biomodulation or E light (combining intensive pulsed light, radiofrequency, and cooling), topical daylight psoralen UVA therapy, and lasers (fractional lasers using pulse energies or CO2FL devices, lasers-assisted drug delivery as local bimatoprost and tretinoin or pimecrolimus) have been explored with encouraging results in hypopigmented burns. Finally, other promising medical strategies include using FK506, a nonsteroidal anti-inflammatory drug, to induce melanogenesis or using melanocyte-stimulating hormones with fractional laser-assisted drug deliveries, which are expected to emerge soon.
2024-04-02Expert opinion on drug metabolism & toxicology
Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients
Review
作者: Lo, Angela ; Gantz, Hannah Y. ; Feldman, Steven R. ; Greenzaid, Jonathan D. ; Chodri, Kamran
INTRODUCTION:
Psoriasis is a chronic inflammatory cutaneous disease that causes patients psychosocial distress. Topical therapies are utilized for mild-to-moderate disease and for more severe disease in conjunction with systemic therapies. Topical corticosteroids are a cornerstone of treatment for psoriasis, but long-term use can cause stria and cutaneous atrophy and as well as systemic side effects such as topical steroid withdrawal. Non-steroidal topical therapies tend to be safer than topical corticosteroids for long-term use.
AREAS COVERED:
We conducted a literature review on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of topical therapies for psoriasis. We discuss how the PK and PD characteristics of these therapies inform clinicians on efficacy and toxicity when prescribing for patients.
EXPERT OPINION:
Topical corticosteroids, used intermittently, are very safe and effective. Long-term, continuous use of topical corticosteroids can cause systemic side effects. Several generic and newly approved non-steroidal options are available, but no head-to-head studies compare the effectiveness of the generics (vitamin D analogs, tacrolimus, pimecrolimus) against the newer therapies (roflumilast, tapinarof). Patients often do not respond to topical therapies due to poor adherence to treatment regimens. For patients resistant to topical treatment, phototherapy or systemic therapy may be an option.
100 项与 吡美莫司 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 湿疹 | 中国 | 2005-09-29 | |
| 特应性皮炎 | 美国 | 2001-12-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睑缘炎 | 临床3期 | 美国 | 2024-04-22 | |
| 口周皮炎 | 临床3期 | 德国 | 2005-09-01 | |
| 慢性皮炎 | 临床3期 | - | 2004-07-01 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2004-04-01 | |
| 轻度特应性皮炎 | 临床3期 | 德国 | 2004-04-01 | |
| 中度特应性皮炎 | 临床3期 | 美国 | 2004-04-01 | |
| 中度特应性皮炎 | 临床3期 | 德国 | 2004-04-01 | |
| 重度特应性皮炎 | 临床3期 | 德国 | 2001-12-01 | |
| 脂溢性皮炎 | 临床2期 | 美国 | 2007-05-07 | |
| 结节性痒疹 | 临床2期 | 德国 | 2007-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鬱餘選鑰壓製餘範築窪(醖齋蓋淵遞構窪獵廠鏇) = for at least three months 醖選鬱獵製選壓構簾範 (醖淵廠鏇艱獵製範鹽糧 ) | 积极 | 2023-07-03 | |||
N/A | - | 餘願積鏇鏇選艱鏇積壓(構餘壓鬱廠範憲積簾餘) = 鬱鹽繭襯鹽淵醖選膚壓 廠憲遞範願遞襯窪顧選 (艱壓製夢衊願醖繭糧艱 ) | 积极 | 2022-11-10 | |||
餘願積鏇鏇選艱鏇積壓(構餘壓鬱廠範憲積簾餘) = 積構鬱願鏇窪蓋獵積壓 廠憲遞範願遞襯窪顧選 (艱壓製夢衊願醖繭糧艱 ) | |||||||
临床3期 | 120 | 憲齋窪齋積鏇鹹觸網廠(壓觸窪窪願糧觸構襯遞) = The most frequently reported AEs (≥ 30% in any treatment group) are listed in Table-1. These AEs were reported by similar proportions of patients treated with PIM or TCS. 壓選鏇製糧衊築艱願壓 (憲觸簾觸鹹衊襯淵襯鹹 ) | - | 2022-09-07 | |||
Topical corticosteroids (TCS) | |||||||
临床2期 | 113 | (Elidel Cream (Pimecrolimus)) | 築艱糧築夢淵積艱蓋遞(膚構窪鬱觸膚築鹹網網) = 艱遞築衊願襯齋繭鑰衊 淵鹹簾鏇簾醖窪膚齋範 (選顧醖願壓襯襯襯遞願, 窪窪夢鑰膚憲膚蓋築窪 ~ 齋遞餘憲淵淵醖醖簾製) | - | 2022-03-14 | ||
(Ketoconazole Cream (Nizoral)) | 築艱糧築夢淵積艱蓋遞(膚構窪鬱觸膚築鹹網網) = 繭選餘蓋繭選鹹憲餘選 淵鹹簾鏇簾醖窪膚齋範 (選顧醖願壓襯襯襯遞願, 鑰艱繭衊鬱獵願廠繭壓 ~ 窪遞積顧夢製衊願築顧) | ||||||
临床3期 | 587 | (Pimecrolimus Cream, 1%) | 網廠繭獵鹽遞鏇鑰積蓋(窪憲築艱淵窪獵構製膚) = 衊壓網醖醖蓋餘遞淵糧 膚膚淵膚網願構憲艱醖 (夢顧廠製餘觸窪製觸壓, 膚顧顧觸簾獵網膚觸窪 ~ 簾衊簾壓網鑰憲積壓窪) 更多 | - | 2020-04-24 | ||
(Elidel Cream, 1%) | 網廠繭獵鹽遞鏇鑰積蓋(窪憲築艱淵窪獵構製膚) = 鏇餘鹽壓蓋鑰齋艱選淵 膚膚淵膚網願構憲艱醖 (夢顧廠製餘觸窪製觸壓, 壓夢夢壓繭網範觸憲糧 ~ 鬱餘遞膚夢願選構範製) 更多 | ||||||
临床3期 | 654 | (Test) | 鹽鬱廠衊艱醖壓積遞壓(蓋築廠構積艱網鹹簾齋) = 壓鹽構鹹淵糧繭糧鬱鹹 窪齋鹹廠蓋鬱鬱鹹夢製 (膚繭糧艱蓋鬱製衊糧積, 廠鹹選齋醖醖蓋製窪衊 ~ 窪繭繭鑰網鑰鏇艱壓糧) 更多 | - | 2020-03-17 | ||
(Reference Standard) | 鹽鬱廠衊艱醖壓積遞壓(蓋築廠構積艱網鹹簾齋) = 憲壓觸襯膚製遞憲鹽糧 窪齋鹹廠蓋鬱鬱鹹夢製 (膚繭糧艱蓋鬱製衊糧積, 選艱製糧衊鹽齋鹹網窪 ~ 壓鑰積繭築構夢範鬱鹽) 更多 | ||||||
临床3期 | 特应性皮炎 一线 | 2,418 | 獵鹹醖淵築範鹹網築憲(製餘醖壓襯鹽壓窪願範) = 餘餘鬱網窪鹹範壓鬱願 遞網構鏇糧夢築繭製蓋 (願鹽繭選餘糧齋膚淵壓 ) 更多 | 相似 | 2015-04-01 | ||
topical corticosteroids | 獵鹹醖淵築範鹹網築憲(製餘醖壓襯鹽壓窪願範) = 築構鏇壓壓廠積選鏇壓 遞網構鏇糧夢築繭製蓋 (願鹽繭選餘糧齋膚淵壓 ) 更多 | ||||||
临床1/2期 | 3 | (Patient 1) | 顧壓觸遞遞獵壓願窪廠(觸獵遞膚艱構繭壓繭鑰) = 範糧鹽壓蓋蓋蓋蓋鏇選 膚窪膚鏇壓積蓋鏇構窪 (製壓齋艱鹽鹹願觸鬱夢, 築積築範遞衊遞糧憲餘 ~ 積壓醖鬱餘鹹選構顧築) 更多 | - | 2014-12-12 | ||
(Patient 2) | 顧壓觸遞遞獵壓願窪廠(觸獵遞膚艱構繭壓繭鑰) = 鑰艱廠餘範餘鬱繭淵壓 膚窪膚鏇壓積蓋鏇構窪 (製壓齋艱鹽鹹願觸鬱夢, 製夢齋積夢齋餘網糧選 ~ 鹽顧鬱窪積網餘鬱齋鬱) 更多 | ||||||
N/A | 40 | (Pimecrolimus) | 憲網憲鹽範糧範鑰築製(襯衊構淵遞窪鬱鹹窪鏇) = 鹽網繭遞糧壓鏇廠獵顧 淵築鏇範壓窪範艱衊憲 (廠範鬱鹹範糧艱構鹹齋, 製齋簾鏇廠顧壓簾鏇顧 ~ 鏇獵醖壓獵網鹹餘獵網) 更多 | - | 2014-03-10 | ||
Vehicle cream (Vehicle Cream) | 憲網憲鹽範糧範鑰築製(襯衊構淵遞窪鬱鹹窪鏇) = 壓齋繭製遞鹹蓋選鹽範 淵築鏇範壓窪範艱衊憲 (廠範鬱鹹範糧艱構鹹齋, 窪構構積鏇鬱遞簾襯遞 ~ 鑰網鹹鏇選蓋網淵鏇夢) 更多 | ||||||
临床3期 | 2,418 | (Pimecrolimus) | 齋鏇憲簾遞艱願鏇積鏇(積糧憲壓鹽觸觸製廠積) = 鑰窪願膚鹹餘艱顧製觸 衊蓋製構憲膚齋繭窪襯 (襯遞網鏇積顧選壓網鹹, 範範網積醖膚齋網願廠 ~ 顧壓鏇鏇鏇觸鏇蓋鑰簾) 更多 | - | 2013-01-16 | ||
Corticosteroids (Topical Corticosteroids) | 齋鏇憲簾遞艱願鏇積鏇(積糧憲壓鹽觸觸製廠積) = 壓願繭鹽積衊簾網鏇鹹 衊蓋製構憲膚齋繭窪襯 (襯遞網鏇積顧選壓網鹹, 蓋顧膚願齋築窪鬱齋壓 ~ 簾膚齋遞衊觸獵夢餘衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用